QWhat is the mechanism of action of deucravacitinib?

Richard Winkelmann, DO

Richard Winkelmann, DO

Director for Dermatology and Mohs Surgery
Optum Care
Los Angeles, CA

Deucravacitinib is an oral medication with selective inhibition of tyrosine kinase 2 (TYK2). It binds to the inactive pseudokinase regulatory domain of TYK2 stabilizing its interaction between regulatory and catalytic domains. TYK2 mediates multiple cytokine pathways including IL-23 which in turn impacts the production of IL-17. Deucravacitinib is FDA approved for treatment in adults with moderate to severe plaque psoriasis.


  1. SM Hoy. Drugs, 2022.
  2. SOTYKTU [package insert]. Bristol-Myers Squibb Company, 2022.